242 related articles for article (PubMed ID: 25952661)
1. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII.
Shah A; Delesen H; Garger S; Lalezari S
Haemophilia; 2015 Nov; 21(6):766-71. PubMed ID: 25952661
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
Oldenburg J; Windyga J; Hampton K; Lalezari S; Tseneklidou-Stoeter D; Beckmann H; Maas Enriquez M
Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
[TBL] [Abstract][Full Text] [Related]
3. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.
Garmann D; McLeay S; Shah A; Vis P; Maas Enriquez M; Ploeger BA
Haemophilia; 2017 Jul; 23(4):528-537. PubMed ID: 28220555
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
[TBL] [Abstract][Full Text] [Related]
6. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
Coyle TE; Reding MT; Lin JC; Michaels LA; Shah A; Powell J
J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
[TBL] [Abstract][Full Text] [Related]
8. BAY 81-8973 (Octocog Alfa; Kovaltry
Keating GM
BioDrugs; 2016 Oct; 30(5):453-459. PubMed ID: 27577234
[TBL] [Abstract][Full Text] [Related]
9. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
Kitchen S; Katterle Y; Beckmann H; Maas Enriquez M
J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
[TBL] [Abstract][Full Text] [Related]
10. Increased branching and sialylation of N-linked glycans correlate with an improved pharmacokinetic profile for BAY 81-8973 compared with other full-length rFVIII products.
Teare JM; Kates DS; Shah A; Garger S
Drug Des Devel Ther; 2019; 13():941-948. PubMed ID: 30962676
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Yoshioka A
Int J Hematol; 2000 Jul; 72(1):101-7. PubMed ID: 10979218
[TBL] [Abstract][Full Text] [Related]
13. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials.
Kenet G; Moulton T; Wicklund BM; Ahuja SP; Escobar M; Mahlangu J
J Blood Med; 2023; 14():379-388. PubMed ID: 37309365
[TBL] [Abstract][Full Text] [Related]
14. BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review.
Mahlangu JN; Ahuja SP; Windyga J; Church N; Shah A; Schwartz L
Ther Adv Hematol; 2018 Jul; 9(7):191-205. PubMed ID: 30013766
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
Yang R; Sun J; Zhao Y; Wang X; Wu D; Tseneklidou-Stoeter D; Wu J; Church N
Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
[TBL] [Abstract][Full Text] [Related]
16. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
Shah A; Solms A; Garmann D; Katterle Y; Avramova V; Simeonov S; Lissitchkov T
Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
Fujii T; Hanabusa H; Shima M; Morinaga T; Fukutake K
Int J Hematol; 2017 Mar; 105(3):280-286. PubMed ID: 27832514
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
